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Activation of human Vγ9/Vδ2 T cells by “phosphoantigens” (pAg), the microbial metab-
olite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) and the endogenous 
isoprenoid intermediate isopentenyl pyrophosphate, requires expression of butyrophilin 
BTN3A molecules by presenting cells. However, the precise mechanism of activation of 
Vγ9/Vδ2 T cells by BTN3A molecules remains elusive. It is not clear what conformation 
of the three BTN3A isoforms transmits activation signals nor how externally delivered 
pAg accesses the cytosolic B30.2 domain of BTN3A1. To approach these problems, 
we studied two HLA haplo-identical HeLa cell lines, termed HeLa-L and HeLa-M, which 
showed marked differences in pAg-dependent stimulation of Vγ9/Vδ2 T  cells. Levels 
of IFN-γ secretion by Vγ9/Vδ2 T cells were profoundly increased by pAg loading, or by 
binding of the pan-BTN3A specific agonist antibody CD277 20.1, in HeLa-M compared 
to HeLa-L cells. IL-2 production from a murine hybridoma T cell line expressing human 
Vγ9/Vδ2 T cell receptor (TCR) transgenes confirmed that the differential responsiveness 
to HeLa-L and HeLa-M was TCR dependent. By tissue typing, both HeLa lines were 
shown to be genetically identical and full-length transcripts of the three BTN3A isoforms 
were detected in equal abundance with no sequence variation. Expression of BTN3A 
and interacting molecules, such as periplakin or RhoB, did not account for the functional 
variation between HeLa-L and HeLa-M cells. Instead, the data implicate a checkpoint 
controlling BTN3A1 stability and protein trafficking, acting at an early time point in its 
maturation. In addition, plasma membrane profiling was used to identify proteins upreg-
ulated in HMB-PP-treated HeLa-M. ABCG2, a member of the ATP-binding cassette 
(ABC) transporter family was the most significant candidate, which crucially showed 
reduced expression in HeLa-L. Expression of a subset of ABC transporters, including 
ABCA1 and ABCG1, correlated with efficiency of T cell activation by cytokine secretion, 
although direct evidence of a functional role was not obtained by knockdown experi-
ments. Our findings indicate a link between members of the ABC protein superfamily 
and the BTN3A-dependent activation of γδ T cells by endogenous and exogenous pAg.
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inTrODUcTiOn
Gammadelta (γδ) T cells are a lineage of innate-like “unconven-
tional” T lymphocytes with potent cytotoxic, pro-inflammatory, 
and regulatory properties. They express, as a defining feature, a 
T cell receptor (TCR) composed of a γ and δ chain heterodimer, 
both products of V(D)J recombination, which distinguishes them 
from conventional αβ T cells (1).
Although often restricted to distinct anatomical locations 
including skin and intestinal epithelium, both major sites of 
host interaction with the microbiota and of pathogen entry, 
the role of γδ T cells in tissue immune surveillance is not fully 
understood (2, 3). Butyrophilins (BTNs) appear to be pivotal in 
the maintenance of immune homeostasis in tissue epithelium by 
controlling the activation of γδ T cells (4). The observed homol-
ogy to co-receptors, such as CD80, CD86, and PD-L1 (5), initially 
suggested the possibility of ligands for BTN molecules expressed 
on the surface of T cells, although identification of such receptors 
has remained elusive so far (6). Some data are consistent with a 
direct interaction with the γδ TCR, although this remains to be 
confirmed (7–9).
Our work aims to understand the function of BTNs in the 
regulation of γδ T cells and how their dysregulation may con-
tribute to disease. We study the human BTN3A proteins and 
their role in the activation of Vγ9/Vδ2 T cells, a prominent γδ 
T  cell lineage in human blood and tissues (10). A mandatory 
role for paired BTN3A molecules in controlling Vγ9/Vδ2 
T cell activation has been shown recently (11), and other BTN 
and BTN-like molecules both in mouse and in humans may 
similarly control defined γδ T cell subsets. For example, Skint1 
determines the Vγ5/Vδ1 dendritic epidermal T cell lineage in 
murine skin (12, 13), Btnl1 controls the Vγ7+ mouse enterocyte 
γδ T cell compartment, and BTNL3 and BTNL8 control human 
colonic Vγ4+ γδ T cells (4). Therefore, this work is likely to be 
relevant to other systems of γδ T cell selection, homeostasis, and 
antigen-dependent activation.
The Vγ9/Vδ2 lineage of γδ T cells is known to be activated 
by exposure to specific “phosphoantigens” (pAg), isopentenyl 
pyrophosphate (IPP) and (E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate (HMB-PP). IPP is a ubiquitous metabolite in all 
living cells and the common end product both of the classical 
mevalonate (also called the HMG-CoA reductase) pathway 
in eukaryotes and some bacteria and of the alternative non-
mevalonate pathway in Gram-negative bacteria, mycobacteria, 
and malaria parasites. The microbial metabolite HMB-PP is an 
intermediate of the non-mevalonate pathway, showing 4log10 
greater activity over IPP (14, 15). While IPP has a lower bioac-
tivity on Vγ9/Vδ2 T cells in cell culture and lower affinity for 
the B30.2 domain of BTN3A1 in binding assays compared to 
HMB-PP, IPP may still play a physiological role in vivo. This may 
be the case where intracellular IPP levels are elevated as a result 
of dysregulation of the mevalonate pathway, for instance upon 
treatment of target cells with aminobisphosphonate drugs such 
as zoledronate, by infection or cellular transformation (16, 17).
In addition to cytokine production and cytotoxicity, Vγ9/
Vδ2 cells promote conventional peptide antigen presentation via 
MHC-I- and MHC-II-dependent mechanisms (18–20) and are 
being investigated as potential tools in cancer immunotherapy 
(21–26). Further, while γδ T cells generally are linked to inflam-
matory and autoimmune responses (27, 28), the contribution 
of the Vγ9/Vδ2 lineage to autoimmune pathology has not been 
addressed. In these contexts, understanding the molecular basis 
of their activation by BTN3A-dependent pAg presentation should 
facilitate their therapeutic manipulation (29).
In initial screens, we identified two HeLa cell lines which dif-
fered markedly in their ability to elicit cytokine from cocultured 
γδ T cells. We have used this model to investigate the function 
of BTN3A molecules in this process and to identify novel com-
ponents. The data indicate that environmental exposure, such as 
treatment of cells with the cytotoxic anticancer drug doxorubicin 
(DOX), may influence γδ T  cell activation by regulation of 
BTN3A protein stability or trafficking and expression of ATP-
binding cassette (ABC) transporters via the KEAP1/NRF2 stress 
response pathway.
MaTerials anD MeThODs
expression constructs
Primer sequences are listed in Table S1 in Supplementary 
Material. DNA encoding specific shRNA oligos directed to 
BTN3A isoforms, periplakin, and ABCG2 were cloned into pHR-
SIREN/puro using BamHI/EcoRI as described previously (30). 
Virus particles were produced by co-transfection of 293T  cells 
with pCMV8.91 (gag-pol) and pMDG (VSV-G env) plasmids. 
Supernatant was harvested after 48 h, filtered, and used to trans-
duce HeLa cells. Clones were selected by puromycin (1 µg/ml) 
for 24 h. shRNA oligonucleotide sequence targeting all BTN3A 
isoforms was: shBTN3A.CGTGTATGCAGATGGAAAG. For 
re-expression, HeLa shRNABTN3A cells were co-transduced with 
lentivirus carrying variant BTN3A1 sequences. Green fluorescent 
protein (GFP) positive cells were sorted using BD FACSAria cell 
sorter.
cell lines and Dna constructs
HeLa-M (a gift from Dick van den Boomen CIMR, Cambridge) 
and HeLa-L (from Will McEwan, MRC-LMB, Cambridge) 
cervical carcinoma cells were grown in standard tissue culture 
conditions using RPMI-1640 medium plus 10% FCS, penicillin/
streptomycin (100 U/ml) and l-glutamine (2 mM). Cells were 
routinely checked for mycoplasma (MycoAlert Lonza LT07-
218). HLA typing was performed by Addenbrooke’s Hospital 
Histocompatibility and Immunogenetics (Tissue Typing) labo-
ratory. Human embryonic kidney 293T and bladder carcinoma 
EJ28 cells were also grown in supplemented RPMI-1640 
medium. Human foreskin fibroblasts HFF-T and fetal lung 
MRC-5T, both immortalized by expression of hTERT, the cata-
lytic subunit of human telomerase (a gift of Stephen Graham, 
Department of Pathology) were grown in supplemented DMEM 
medium.
Cells (1 ×  105) growing in six-well plates were transfected 
with DNA expression constructs using Fugene (Promega). For 
RT-PCR, total RNA was prepared from cultured cells using 
RNAeasy mini (Qiagen) and Superscript III (Invitrogen) used to 
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produce first strand cDNA. Amplification was carried out using 
2× BiomixRed Taq polymerase (Bioline). RT-PCR products were 
analyzed by gel electrophoresis and cloned using Zero-Blunt 
Topo (Invitrogen).
Killing assay was by propidium iodide (PI) dye exclusion in 
cells treated with doxorubicin DOX (Cell Signaling). Cells were 
harvested and stained in 100  µl PBS (2.5  µg/ml PI) for 5  min 
before washing and analysis by fluorescence activated cell sorting 
(FACS) on a BD FACScalibur and data points collected on FL3/
FSC. Inhibitors MG132 (5 µM for 5 h) and bafilomycin A (bafA) 
(5 µM 10 h) were used in cell assays. For activation, supernatants 
were collected from 24 h cocultures of Vγ9/Vδ2 T and HeLa-M 
cells containing 10 nM HMB-PP (Echelon) and used at a 1/10 
dilution for 24 and 48 h.
immunoblot and Quantitative Mass 
spectroscopy of surface-Biotinylated 
Proteins
Cell lysates were prepared in buffer (50  mM Tris–Cl pH 7.5, 
150  mM NaCl, 1% Triton-X, EDTA-free protease inhibitor, 
Roche) by incubation for 10  min at 4°C, then pre-cleared by 
centrifugation. For immune blots, cleared lysates were solubi-
lized in SDS-PAGE buffer (5 min, 95°C) and separated in 10% 
SDS-PAGE gels (NextGel) then transferred to PVDF membrane. 
Antibodies were added directly to blocked membranes (5% 
Marvel/PBS 0.1% Tween 20) and incubated for 1 h with primary 
and HRP-conjugated secondary antibodies. Blots were visualized 
with ECL reagent (GEhealthcare) before exposure to X-ray film 
(Fuji). Monoclonal CD277 20.1 (LifeSpanBio), NRF2 (AF3925 
R&D Systems), ABCG2 (ab108312) anti-calnexin (3811-100), 
and anti-GFP (SAB4301138) were used as well as 056 and B6 rab-
bit anti-B30.2 polyclonal sera at concentration between 0.5 and 
1 µg/ml (30). Cell fractionation was carried out using Qproteome 
cell compartment kit (Qiagen).
For plasma membrane profiling (PMP), HeLa-M cells 
(5  ×  107) in large T175 flasks were either left untreated or 
treated with HMB-PP (10  nM for 10  h). Cells were washed 
(1× PBS) then biotinylation reagents added (30  min at 4°C). 
After quenching, cells were harvested by scraping and pro-
cessed for immunoprecipitation, by lysis in 1% Tx-100 TBS pH 
8 buffer with protease inhibitor (Complete EDTA free, Roche) 
and end-over-end rotation for 30 min at 4°C. After centrifuga-
tion (10,000 g for 10 min), Streptavidin agarose resin (Thermo 
Fisher) was added to supernatants, with incubation for 2 h at 
4°C. Agarose beads were washed (20×) in lysis buffer, 20× in 
0.5% SDS in PBS, 20× in 6 M urea/triethylammonium bicar-
bonate (TEAB) pH 8.5, 5× in TEAB pH 8.5 before digestion 
overnight with 0.5 µg trypsin in a final volume of 50 µl TEAB 
(31). Resulting peptides were analyzed by LC-MS/MS analysis 
using an Orbitrap Fusion instrument (Thermo Fisher) utilizing 
a 60-min gradient. Raw data were searched using MASCOT 
from within Proteome Discoverer (Thermo Fisher) v2.0 against 
the Uniprot human reference proteome. Peptide identifications 
were controlled at 1% FDR using Mascot Percolator. Proteins 
were quantified in a label-free manner using the precursor ion 
quantifier node.
T cell assays
Ethical approval for working with blood samples from healthy 
donors was obtained from the South East Wales Local Ethics 
Committee (08/WSE04/17) and the Cambridge Local Ethics 
Committee (HBREC.2015.27). All volunteers provided written 
informed consent.
Vγ9/Vδ2 T  cells were expanded from peripheral blood 
mononuclear cells of healthy donors with 1  µM zoledronate 
(Zometa; Novartis) and 50 U/ml IL-2 (Proleukin, Chiron) for 
14  days and further enriched to purities >98% CD3+ Vγ9+ 
by negative selection using a modified human γδ T cell isola-
tion kit that depletes B  cells, αβ T  cells, NK  cells, dendritic 
cells, stem cells, granulocytes, and monocytes (Stem Cell 
Technologies). Unless otherwise stated, target HeLa cells were 
pretreated with 10  µM zoledronate or 10  nM HMB-PP, then 
washed extensively before coculture with γδ T cells at a ratio 
of 1:10 (104 target: 105T effector cells). The amount of IFN-γ 
secreted into the culture supernatant over 24 h was measured 
by ELISA (eBioscience). Mobilization of CD107a onto the cell 
surface over the first 5 h of coculture was determined using a 
PE-conjugated anti-CD107a antibody (H4A3; BD Biosciences) 
in the presence of monensin at a 1:2,000 dilution (GolgiStop). 
Cells were acquired on a FACS Canto II and analyzed with 
FlowJo. HeLa cells were also incubated with agonist CD277 
20.1 monoclonal antibody (eBioscence) to induce activation 
independently of phosphoantigen.
The murine T cell hybridoma 53/4r/mCD28 TCR MOP was 
used to test Vγ9/Vδ2 TCR mediated activation, as described 
(32). In these experiments, HeLa cells used as stimulators (104) 
were seeded in 96-well flat bottom tissue culture plate, allowed 
to adhere for 1  day before addition of T  cells in fresh culture 
medium. Production of mouse IL-2 in culture supernatants was 
tested with a commercial mouse IL-2 ELISA kit.
resUlTs
Two haplo-identical hela cell lines, 
hela-l and hela-M, show Marked 
Variation in Their ability to activate  
Vγ9/Vδ2 T cells via BTn3a
Various tumor-derived and primary epithelial cell lines were 
tested for their ability to respond to the aminobisphosphonate 
drug zoledronate and present the microbial compound HMB-PP 
to Vγ9/Vδ2 T  cells (Figure S1A in Supplementary Material). 
Two HeLa cervical epithelium carcinoma cell lines, HeLa-L 
and HeLa-M, showed profound differences in their ability to 
elicit cytokine (Figure 1; Figure S1 in Supplementary Material). 
HeLa-M cells were far more potent than HeLa-L cells in stimulat-
ing release of IFN-γ (Figure 1A; Figure S1B in Supplementary 
Material) and TNF-α (Figure S1C in Supplementary Material) 
upon pretreatment with HMB-PP. Responses to zoledronate 
similarly differed between the two cell lines (data not shown). 
Responses to either HeLa cell line were abrogated by expression 
of a single shRNA targeting the three BTN3A isoforms (shRN-
ABTN3A cells), confirming the importance of BTN3A in mediating 
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FigUre 1 | HLA haplo-identical HeLa-L and HeLa-M cells vary in their ability 
to present phosphoantigens to Vγ9Vδ2 T cells. (a) Vγ9/Vδ2 T cell activation 
as detected by production of IFN-γ. Wild-type and shRNABTN3A HeLa-L and 
HeLa-M cells were pretreated with hydroxy-3-methyl-but-2-enyl 
pyrophosphate (HMB-PP) (10 nM for 5 h) before addition of expanded  
Vγ9/Vδ2 T cells at E:T ratio of 10:1. After overnight incubation, culture 
supernatants were analyzed by ELISA. Bar chart shows mean and SD from 
triplicate measurements using T cells from one donor and is representative  
of three independent experiments using T cells from separate donors.  
(B) Knockdown of BTN3A expression by shRNA expression in HeLa cells. 
Transcripts for BTN3A and β-actin were amplified by RT-PCR from wild-type 
and shRNABTN3A HeLa-L and HeLa-M cDNA template and products analyzed 
by gel electrophoresis. PCR results shown are representative of three 
independent experiments. (c) Activation of Vγ9/Vδ2 T cells detected by 
ELISA for IFN-γ as in (a) using a concentration gradient of HMB-PP, agonist 
antibody CD277 20.1 and T cells expanded from two separate donors. 
Activation was induced by pretreatment of HeLa cells using HMB-PP for 5 h 
(left panel) and anti-BTN3A monoclonal antibody 20.1 for 30 min (right panel). 
Graphs show mean and SD from n = 2 and are representative of two 
independent measurements. (D) Activation of Vγ9/Vδ2 T cells as detected by 
flow cytometry for percent double positive Vγ9 and CD107a cells after 
coculture experiments as in (c).
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Vγ9/Vδ2 T  cell responses to both HMB-PP and zoledronate 
(Figures 1A,B).
The differential responsiveness of Vγ9/Vδ2 T cells to HeLa-L 
and HeLa-M cells was replicated when using the pan-BTN3A 
specific agonist antibody CD277 20.1, which induces BTN3A-
dependent activation of Vγ9/Vδ2 T cell activation in the absence 
of HMB-PP or zoledronate (Figure 1C). In addition, production 
of IL-2 from a murine T  cell hybridoma expressing human 
Vγ9/Vδ2 transgenes showed a similar differential response to 
HMB-PP (Figure S1D in Supplementary Material).
In striking contrast to these findings of cytokine secretion as 
a functional read-out for T cell responses, surface mobilization 
of CD107a/LAMP1 did not differ between Vγ9/Vδ2 T  cells 
responding to the two HeLa lines, upon HMB-PP or CD277 
20.1 antibody pretreatment (Figure 1D), indicating differential 
signaling requirements for the induction of cytokine secretion 
versus CD107a mobilization.
Taken together, these experiments demonstrated that HeLa-M 
cells were more efficient at activating Vγ9/Vδ2 T cells via BTN3A 
than HeLa-L cells, with regard to the induction of cytokine 
expression but not CD107a mobilization. These cell lines, there-
fore, represent a useful experimental model to investigate the 
molecular mechanism underlying the specific Vγ9/Vδ2 T  cell 
responses to endogenous and exogenous pAg.
BTn3a Transcripts are identical in  
hela-l and hela-M
In order to account for the functional differences between HeLa-L 
and HeLa-M cells, full-length BTN3A transcripts were amplified 
by RT-PCR from HeLa cDNA, cloned, and sequenced (Figure 2). 
As shown in Figure 2A, transcripts of all three BTN3A isoforms 
were expressed at comparable levels in both HeLa-L and HeLa-M, 
with no differences in splicing and all were targeted with equal 
efficiently by shRNA. No sequence variation or mutation was 
detected when six clones from each cell line for each BTN3A 
isoform were compared to consensus sequences (BTN3A1 
NM_007048, BTN3A2 NM_007047, BTN3A3 NM_006994) 
(data not shown). Known synonymous SNPs common in sub-
Saharan Africa, but rare in other populations, were identified 
in all BTN3A1 sequences (dbSNP rs3857550, rs2393650, and 
rs537072716), suggesting that both HeLa lines were homozygous 
for these polymorphisms. BTN3A2 and BTN3A3 nucleotide 
sequences showed no polymorphisms; however, allelic exclusion 
or haplotype bias in transcript expression was not assessed. By 
tissue typing of genomic DNA, both HeLa cell lines were HLA-
A68-B15:03/15 -Bw6 -C12 -DR 01:02/01:2601 haplo-identical. 
These data provided convincing authentication of the HeLa lines 
by conformation of their common genetic origin.
cellular Markers of activation are 
Unaffected
Transcripts for BTN3A1 were shown to be induced by type I and 
type II interferons and HeLa-L and HeLa-M cells did not differ in 
this regard (Figure 2B and data not shown). By cytometry, there 
was comparable upregulation of surface MHC-I and MHC-II by 
IFN-γ treatment; however surface staining using CD277 20.1 
antibody was not detected, indicating a discrepancy between 
transcriptional regulation and protein expression (Figure 2C).
In order to investigate the possibility of a soluble factor influ-
encing T cell activation and also a more physiologically relevant 
stimulus potentially influencing BTN3A1 expression, we studied 
the response of both HeLa lines to treatment with supernatants 
collected from 24  h cocultures of Vγ9/Vδ2 T  cells activated 
with HMB-PP (10 nM) loaded HeLa-M cells. Transcripts for a 
FigUre 2 | Transcripts for the three BTN3A isoforms are unchanged in HeLa-L 
and HeLa-M. (a) Amplification of full-length BTN3A1, BTN3A2, and BTN3A3 
transcripts by RT-PCR from wild-type and shRNABTN3A HeLa-L and HeLa-M 
cDNA template. (B) RT-PCR for BTN3A1, BTN2A1, and MHC-II (DMα) from 
cDNA derived from HeLa-M cells either left untreated or treated with IFN-α or 
IFN-γ. RT-PCR products were analyzed by gel electrophoresis, with β-actin as 
loading control. Results are representative of three experiments. (c) Analysis of 
activation markers MHC-I (w6/32), MHC-II (L243), and BTN3A (CD277 20.1)  
by flow cytometry in HeLa cells treated with or without IFN-γ. Results 
representative of triplicate experiments. Red lines indicate IFN-γ treated and 
black lines untreated samples. Solid lines are HeLa-M and dotted lines HeLa-L. 
(D) Expression of activation markers as detected by RT-PCR in HeLa-L and 
HeLa-M cells left untreated or treated with γδ T/HeLa-M cell coculture 
supernatant collected as described (see Materials and Methods). Transcripts for 
BTN3A1, HLA-E, DMα, CIITA, TRIM21, CXCL10, IDO-1, and BTN2A1 were 
amplified and visualized by gel electrophoresis. Results are representative of 
duplicate experiments. (e) Expression of the BTN3A1 interacting molecules 
protein periplakin (PPL) and RhoB in treated and untreated HeLa-L and 
HeLa-M cells analyzed by RT-PCR, as in (c), with transcripts for β-actin as a 
loading control. Results are representative of duplicate experiments. (F) Lysates 
from HeLa-L and HeLa-M cells left untreated or treated with γδ T/HeLa-M cell 
coculture supernatant or IFN-γ, were analyzed by western blot for expression of 
PPL protein. Duplicate blots were probed with calnexin (CNX) antibody as a 
loading control. (g) Cell fractionation to compare the sub-cellular distribution of 
PPL protein in HeLa-L and HeLa-M cells. Fractions for soluble (1), membrane 
(2), nuclear (3), and cytoskeletal/detergent resistant membrane (4) fractions 
were prepared and analyzed by western blot using anti-PPL, β-tubulin, CNX, 
and β-actin antibodies.
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number of activation markers, including MHC-II DMα, HLA-E, 
MHC-II trans-activator CIITA, and TRIM21 were analyzed by 
RT-PCR in addition to BTN3A1 (Figure 2D). Some variation in 
HeLa-derived transcripts was detected, particularly CXCL10 and 
IDO-1 and a slight increase in BTN3A1 transcripts upon activa-
tion in HeLa-M was not seen in HeLa-L. However, convincing 
BTN3A expression or activation at the cell surface was not detected 
by cytometry using CD277 20.1 antibody as for Figure 2C (data 
not shown). BTN2A1 transcripts did not vary between samples, 
and there was no correlation between butyrophilin BTN2A or 
BTN3A expression and CIITA/MHC-II in HeLa cells (6). A more 
detailed quantitative analysis of some transcripts, for example 
CXCL10 or IDO-1 may be warranted, but the data so far were 
not consistent with a major signaling defect in either HeLa line 
which could account for differential responses in T cell assays or 
with transcriptional control affecting BTN3A1 activation.
no Variation in expression of BTn3a1 
interactors
The cytoskeletal adaptor protein periplakin (PPL) and the RAS- 
superfamily GTPase RhoB were recently identified as BTN3A1 
interacting molecules (30, 33). We tested whether the differen-
tial BTN3A1-dependent responsiveness of Vγ9/Vδ2 T  cells to 
HMB-PP loaded HeLa-L and HeLa-M might be due to variation 
in PPL and/or RhoB expression. In duplicated RT-PCR experi-
ments, transcripts for PPL were slightly more abundant in HeLa-L 
compared to HeLa-M. By analyzing separate domains of the 
mRNA, no variation in splicing which conceivably could affect 
protein interactions or shRNA-mediated transcript suppression 
was detected (Figure 2E). In addition to PPL itself, we detected 
transcripts for the PPL interacting molecule PLEC1 (Figure 2E) 
but not for kazrin or envoplakin (34–36). RhoB transcripts were 
detected abundantly in both HeLa lines and were not obviously 
affected by activation with γδ T cell/HeLa-M coculture superna-
tants. By western blot, major variation in PPL protein level was 
not detected between the HeLa cell lines either with, or without, 
activation using IFN-γ or using T cell supernatants (Figure 2F). 
Neither did we see any discrepancy in cellular distribution by cell 
fractionation; PPL was distributed equally in soluble, membrane, 
nuclear, and cytoskeletal/detergent resistant membrane fractions 
as shown previously (Figure 2G) (30).
These experiments suggested that differences in the expression 
of BTN3A1 interacting molecules did not account for the func-
tional variation between HeLa-L and HeLa-M cells. By contrast, 
in a direct comparison in T cell assays of HeLa-L and HeLa-M 
PPL knockdown lines, produced by expression of three different 
PPL targeting shRNA (Figure S2 in Supplementary Material), 
wide variation in responses as measured by IFN-γ was detected. 
The PPL knockdown experiments were consistent with our initial 
conclusion of a regulatory rather than mandatory role for PPL in 
transmitting activation signals to T cells (30).
Detection of BTn3a1 by re-expression  
in shrnaBTn3a cells
Although mRNA transcripts were detectable, BTN3A proteins 
were not abundantly expressed in HeLa cells. In addition, 
CD277 20.1 antibody binding to HeLa cells was not convincing 
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FigUre 3 | Detection of BTN3A1 by re-expression in shRNABTN3A cells.  
(a) Diagram of BTN3A1 protein and structure of the two principal stimulatory 
phosphoantigens (pAg) hydroxy-3-methyl-but-2-enyl pyrophosphate 
(HMB-PP) and isopentenyl pyrophosphate (IPP). Sites of pAg interaction in 
the BTN3A1 B30.2 domain, protein periplakin (PPL) interaction at the 
juxta-membrane domain (JMD) and the antibodies used for detection are 
highlighted. BTN3A3 has a structure similar to BTN3A1, whereas BTN3A2 is 
truncated after the JMD and lacks the B30.2 domain. (B) Diagram of BTN3A 
pHRsinIRESgfp lentiviral expression vector used in re-expression studies. 
Independent measure of transgene expression is provided by internal 
ribosome entry site (IRES) driven green fluorescent protein (GFP). (c) Western 
blot of HeLa-L cells transiently transfected with expression vectors for 
BTN3A1, BTN3A2, and BTN3A3. Monoclonal anti-BTN3A (CD277 20.1) 
antibody and polyclonal sera 056 and B6, directed to B30.2 domains of 
BTN3A1 and BTN3A3, respectively, were used. Anti-GFP and calnexin (CNX) 
antibodies provided loading controls for expression of transgene and 
endogenous proteins, respectively. (D) Western blot analysis of stable 
BTN3A1 re-expression lines of HeLa-L and HeLa-M shRNABTN3A cells, either 
left untreated or treated with MG132 or bafilomycin A (bafA). Anti-CD277 20.1 
antibody and polyclonal sera 056 were used, together with anti-GFP and CNX 
control antibodies as in (c). Detection of CD277 20.1 and 056 reactive 
protein bands required extended exposure to X-ray film.
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by cyto metry (Figure  2C), despite the fact that this agonistic 
antibody elicited potent Vγ9/Vδ2 T cell activation (Figure 1B). 
In order to overcome the limitations posed by low expression 
levels, we re-expressed BTN3A isoforms in wild-type and BTN3A 
knockdown (shRNABTN3A) cells using a lentiviral vector which 
afforded an independent marker of transgene expression via 
detection of GFP (Figures 3A,B).
By transient transfection of either HeLa-L or HeLa-M with 
expression vectors for BTN3A1, BTN3A2, and BTN3A3, signifi-
cant surface CD277 20.1 antibody staining was not detected for 
any of the three BTN3A isoforms, even with high GFP transgene 
expression (Figure S2A in Supplementary Material). In contrast, 
BTN3A2 and BTN3A3, but not BTN3A1, were productively 
expressed on the surface of 293T cells using the same transfection 
strategy, indicating that surface expression of BTN3A/CD277 
was tightly regulated, by a mechanism which targeted BTN3A1 
preferentially and which differed between cell lines.
By western blot analysis of lysates from transiently transfected 
cells, there was marked variation in the ability of CD277 20.1 
antibody to detect the different BTN3A isoforms (Figure  3C; 
Figure S2B in Supplementary Material). While BTN3A1 was 
barely detectable, BTN3A2 was abundant (at levels expected 
from transgene expression) and BTN3A3 was expressed at inter-
mediate levels. Authentic expression of full-length proteins was 
confirmed in some experiments using isoform specific antisera 
directed against the B30.2 domains of BTN3A1 and BTN3A3 
(Figure  3C; Figure S2 in Supplementary Material), requiring 
extended exposure to X-ray film.
The above experiments indicated an intracellular checkpoint 
to BTN3A1 expression. To determine if this was mediated by pro-
tein degradation, we tested the effect of the proteasome inhibitor 
MG132 and bafA, an inhibitor of lysosome/autophagy pathways, 
on BTN3A1 expression in lentivirally transduced HeLa-L and 
HeLa-M shRNABTN3A cells (Figure  3D). By western blot using 
CD277 20.1 antibody, full-length soluble BTN3A1 (57 kDa) was 
detected in the untreated HeLa-M re-expression line, but was 
barely detectable in the HeLa-L lysate. Instead, a lower molecular 
weight band of 38 kDa was detected in HeLa-L samples, indica-
tive of BTN3A1 protein cleavage. Alternatively, the 38-kDa pro-
tein could represent endogenous BTN3A2, although BTN3A2 
was not detected abundantly in un-transfected cell lines (Figure 
S3 in Supplementary Material). Levels of detergent-soluble, full-
length BTN3A1 were reduced by MG132 treatment, but were 
unaffected by bafA. In contrast, MG132 treatment of HeLa-L 
cells led to the appearance of full-length BTN3A1 (57 kDa) in 
the detergent resistant fractions from Tx-100 lysates, suggest-
ing a potential redistribution of BTN3A1 in the membrane by 
proteasome inhibition.
Taken together, these results were consistent with a mecha nism 
controlling surface expression of BTN3A protein isoforms, in 
particular BTN3A1, by protein production, stability, or trafficking.
PMP of hMB-PP Treated cells identifies 
aBcg2
We next searched for differences in cellular factors that might 
influence pAg presentation in the two HeLa cell lines using 
surface biotinylation, followed by immunoprecipitation and 
quantitative mass spectroscopy (37). Bulk HeLa-M cells were 
allowed to adhere (10 h), then were either left untreated or treated 
with HMB-PP (10 nM for 10 h) prior to PMP as described (38).
By this approach, ABCG2 (also called breast cancer resist-
ance protein) was identified as a candidate whose expression 
was significantly influenced by HMB-PP in HeLa-M cells 
(Figure 4A). ABCG2 is a member of the superfamily of ABC 
transporters and was originally characterized as a drug efflux 
pump (39). Variation in expression was modest (log2 =  2.69 
increase), but several independent peptides of ABCG2 were 
detected. FAM129B, a molecule involved in RAS activation, 
was another candidate potentially affected by HMB-PP treat-
ment (log2 = 2.15 increase) (40). By RT-PCR from the panel of 
untreated versus treated HeLa cDNA (Figure 4B), transcripts for 
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FigUre 4 | Plasma membrane profiling (PMP) by mass spectroscopy 
identifies ABCG2. (a) Table of top hits identified using PMP to compare 
HMB-PP treated and untreated HeLa-M cells. Several independent peptides 
of ATP-binding cassette (ABC) transporter ABCG2 were detected, with 
modest increase (log2 2.69) by treatment. Other potential candidates by these 
criteria (C3orf52 and FAM129B) are listed and were less significant. (B) 
Dysregulation of a subset of ABC transporters, including ABCG2, in HeLa 
cells detected by RT-PCR. Template cDNA was prepared from total RNA from 
HeLa-L and HeLa-M cells left untreated or treated with γδ T cell supernatant 
for 24 h. RT-PCR products were analyzed by gel electrophoresis. (c) Variation 
in ABCG2 protein expression in HeLa cells by western blot. Top panel: HeLa-L 
and HeLa-M cells were left untreated or treated with MG132 (5 µM for 10 h) or 
HMB-PP (10 nM for 10 h). Cell lysates were prepared and analyzed using 
antibodies directed to ABCG2, NRF2, and calnexin (CNX), which acts as a 
loading control. Bottom panel: western blot analysis of shRNAABCG2 cells 
confirms reduction in ABCG2 protein expression. (D) HeLa-M cells show 
ABCG2-dependent resistance to cytotoxic drug doxorubicin (DOX). Wild-type 
HeLa-M, HeLa-L, and shRNAABCG2 HeLa-M cells were incubated (24 h) with 
DOX at the indicated concentrations. Cells were stained using propidium 
iodide (PI) (2.5 µg/ml for 5 min) as a marker of plasma membrane integrity. 
After washing, cells were analyzed by cytometry. Chart shows mean 
fluorescence intensity (MFI) of PI staining. (e) No effect on T cell activation 
using shRNAABCG2 HeLa-M cells. The effect on the efficiency of Vγ9/Vδ2 T cell 
activation for a series of HeLa-M gene knockdown lines, including shRNA 
BTN3A1, ABCG2, RhoB, PLEC1, and TRIM21. Cells were pretreated with 
HMB-PP (10 nM for 6 h) before Vγ9/Vδ2 T cells from a single donor were 
applied. Coculture was allowed to proceed overnight when culture 
supernatants were analyzed by ELISA. Chart shows percent (%) change in 
detected IFN-γ relative to wild-type HeLa-M cells of duplicate determinations 
for each cell line.
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ABCG2 were reduced in HeLa-L compared to HeLa-M samples, 
an observation not seen for other candidates, while FAM129B 
transcripts did not vary (Figures  2C,D). Reduced expression 
of ABCG2 total protein in HeLa-L compared to HeLa-M cell 
lysate was confirmed by western blot (Figure  4C), but varia-
tion in expression by HMB-PP treatment was not and surface 
ABCG2 was not detected by flow cytometry. However, reduced 
levels of ABCG2 by MG132 treatment was seen (Figure  4C), 
similar to that detected for BTN3A1 (Figure  3D). Expression 
of NRF2 (nuclear factor erythroid 2-related factor 2), a basic 
leucine zipper (bZIP) protein and major transcriptional regula-
tor of ABCG2, was stabilized in the MG132 treated samples as 
expected, with increased levels of NRF2 evident in HeLa-M 
versus HeLa-L samples, consistent with the higher expression of 
ABCG2 in these cells (Figure 4C).
From these data, ABCG2 was the most promising candidate to 
account for the differential effects of the HeLa cell lines in T cell 
assays, implicating this molecule in pAg presentation. Therefore, 
HeLa-M cells expressing shRNA targeting ABCG2 (shRNAABCG2) 
were constructed. Reduced ABCG2 expression in shRNAABCG2 
cells was confirmed by western blot (Figure 4C bottom panel) as 
was a functional effect in killing assays, by increased sensitivity to 
DOX, a major target substrate of ABCG2 (Figure 4D). However, 
in coculture assays with Vγ9/Vδ2 T cells, no effect on the efficiency 
of T cell activation of HMB-PP loaded HeLa-M shRNAABCG2 cells 
was detected, as measured by ELISA for IFN-γ (Figure 4E). With 
shRNABTN3A cells acting as control, a modest effect of shRNATRIM21 
cells was detected in these experiments, but no effect of shRNARhoB 
or shRNAPLEC1 cells. RhoB has been implicated previously in pAg 
presentation using similar shRNA-mediated knockdown (33), so 
the lack of specific effects in our experiments may be indicative of 
ineffective transcript suppression or variation between different 
cell lines. The mechanism by which TRIM21 may be affecting γδ 
T cell activation is unexplained (41).
Expression of a number of functionally related ABC trans-
porters was examined by RT-PCR in the activated HeLa cell 
panel, including ABCB1 (multidrug resistance 1, MDR1), 
ABCG1 (white), ABCA1 (cholesterol export regulatory pro-
tein, CERP), ABCC1 (multi-resistance protein 1), and ABCC5 
(multi-resistance protein 5). While expression of the latter two 
(ABCC1 and ABCC5) did not vary, transcripts for ABCB1, 
ABCG1, and ABCA1 did (Figure 4B). ABCB1 showed a pattern 
of expression similar to ABCG2, while ABCG1 and ABCA1 
transcripts were only detected in treated samples of HeLa-L, 
and not in HeLa-M.
Taken together, the results revealed dysregulated expression 
of a subset of ABC transporters, which correlated with efficiency 
of γδ T cell activation, suggesting a link between these members 
of the ABC protein superfamily and pAg-dependent γδ T  cell 
activation.
DiscUssiOn
Butyrophilin BTN3A proteins are the critical determinants of pAg 
presentation to Vγ9/Vδ2 T cells, but their precise role and how 
they are regulated is not fully understood. In order to address this 
issue and with a view to identifying novel effectors, we studied 
two HeLa cell lines which showed marked differences in their 
ability to activate Vγ9/Vδ2 T cells in response to pAg loading. 
Endogenous levels of all BTN3A isoforms were low in HeLa cells 
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and were not detected by western blotting or flow cytometry. By 
PMP using quantitative mass spectroscopy in HeLa-M cells that 
were untreated or treated with HMB-PP, BTN3A1 and BTN3A2 
isoforms were detected at low levels, with minor variation by 
treatment. Subsequent experiments using PMP may allow for 
interrogation of endogenous BTN3A proteins, their regulation 
by pAg and correlation with T cell activation in different present-
ing cells (42).
BTN3A1 protein stability at steady state, where BTN3A1 
transgene re-expression was carefully controlled by GFP, was reduced 
significantly compared to that of the other isoforms, BTN3A2 
and BTN3A3. We also detected differences in BTN3A1 protein 
between the two HeLa cell lines. The data are consistent with 
regulation of BTN3A1 at the level of protein stability. Protein 
truncation, presumably resulting from proteolytic cleavage to 
remove the B30.2 domain was also evident using anti-BTN3A 
antibodies. The possibility that posttranslational modification, for 
instance by N-linked glycosylation, may be influencing CD277 
20.1 antibody recognition of BTN3A1 by affecting protein traf-
ficking and stability cannot be ruled out. It is also unclear whether 
the free B30.2 domain, a potential degradation intermediate, has 
a separate function.
It is possible that specific miRNA or mRNA processing, result-
ing in a block or premature stop in translation could account 
for truncated and/or reduced protein levels, although no effect 
on BTN3A1 transcripts in re-expression lines was detected by 
RT-PCR. Since inhibitor MG132 did not give a clear picture of 
protein stabilization, as exemplified here by stabilization of NRF2, it 
is not clear whether BTN3A1 instability is due to proteasome func-
tion. Lysosomal inhibition also had no effect. Therefore, another 
mechanism of protein maturation and trafficking, acting at the level 
of protein translation or membrane insertion may be involved.
Control of BTN3A1 stability would provide a dynamic mecha-
nism to control Vγ9/Vδ2 T cell activation, similar to that shown 
for the homologous molecule PD-L1 in controlling αβ T  cell 
responses (43). The fact that BN3A1 expression appears to be lim-
iting over BTN3A2 will also influence interactions between the 
two isoforms, proposed recently to be essential for Vγ9/Vδ2 T cell 
activation (11). Regulation of BTN3A1 stability would also offer 
a means to modulate immune-surveillance by Vγ9/Vδ2 T cells, 
representing a potential immune-evasion mechanism exploited 
by tumors and intracellular pathogens.
ABCG2 was identified as a potential candidate protein in pAg- 
dependent T  cell activation using PMP of HMB-PP treated 
HeLa-M cells. ABCG2 correlates functionally with dye negative 
side population, a biomarker of cancer stem cells (44) and was 
considered an interesting functional candidate in pAg presenta-
tion because of the known association with statins, cholesterol 
metabolism, and the HMG-CoA reductase pathway (45, 46). 
However shRNAABCG2 knockdown cells showed no functional 
defect in T cell assays. It is possible that shRNA did not reduce 
ABCG2 levels sufficiently in HeLa-MABCG2 cells to influence this 
assay, or that other members of the ABC transporter family with 
similar expression and substrate profile (for example, ABCB1) 
compensated for its absence in these cells.
In addition to ABCG2 and ABCB1, transcription of ABCA1 
and ABCG1 was dysregulated. ABCA1 and ABCG1 are also 
linked functionally to cholesterol metabolism, acting as regula-
tors of cholesterol transport (47, 48). Since these molecules are 
not known to be induced by pro-inflammatory cytokines, it is 
unclear what signals from the γδ T  cell supernatant, derived 
from cocultures with HeLa-M cells containing 10 nM HMB-PP, 
induced transcription of ABCA1 and ABCG1 in HeLa-L cells 
but not in HeLa-M. Published data describe a role in γδ T cell 
activation for ABCA1 acting together with BTN3A1 as a pAg 
efflux transporter in myeloid cells, linked to the LXR (liver X 
receptor) transcription factor (49). In the ABCA1 efflux model 
(49), ABCA1 drives IPP into the extracellular compartment to 
activate γδ T  cells in trans. In our system, ABCA1 expression 
in activated HeLa-L cells would theoretically reduce intracel-
lular HMB-PP concentration to thereby limit the pool available 
to activate BTN3A1. However, ABCA1 did not enhance T  cell 
activation by HMB-PP-loaded HeLa-M because it did not appear 
to be expressed in these cells. Therefore, ABCA1 alone cannot 
account for the effects we detected, and it is also difficult to resolve 
an extracellular pAg delivery and sensing mechanism with the 
binding of pAg to the cytosolic B30.2 domain of BTN3A1 (9), 
unless this interaction promotes pAg export to bind BTN3A1 
externally, as proposed by other workers (7, 50).
Conventional MHC restricted antigen presentation to TCR 
expressed on αβ T cells relies on peptide transport by the hetero-
dimeric TAP1/2 transporter, and it is plausible that pAg transport 
similarly requires ABC family members. Other workers have 
investigated ABCC5 (51) in addition to ABCA1 (49). Although 
most are described as drug or xenobiotic efflux pumps contribut-
ing to a multidrug resistance phenotype, endogenous substrates 
for many ABC transporters are largely uncharacterized. If these 
ABC transporters are involved, evidently there is more com-
plexity in this system than current models of pAg presentation 
allow, in particular whether pAg transport is into or out of cells 
(or both) (50, 52) and whether they influence BTN3A expression 
by direct interaction (49). Further analysis of these ABC trans-
porters seems warranted.
HeLa cells were the first cell line to be used for biomedical 
research, originating in the 1950s (53). HeLa-L and HeLa-M 
are two sublines the origins of which are obscure but which our 
data so far indicate are genetically identical. The cell lines were 
free of mycoplasma or other detectable infection and the chance 
observation of differences in pAg presentation and interaction 
with expanded Vγ9/Vδ2 T cells derived from different donors 
were stable for over 3 years with repeat samples acquired from 
original sources. The HeLa-M line historically showed elevated 
responses to IFN-γ (54) and in our hands showed resistance 
to the anticancer drug DOX in dye-exclusion killing assay, an 
effect reversed to some extent by ABCG2 knockdown. A fea-
sible scenario, therefore, would be selection by an anticancer 
drug such as DOX resulting in DNA mutation (55), permanent 
activation of the KEAP1/NRF2 stress response pathway and 
increased ABCG2 expression in these cells (56). A similar 
approach was used to identify ABCG2 from a drug-resistant 
MCF-7 line (57).
Alternatively, signaling defects of the hedgehog pathway or 
LXR transcriptional regulation may be involved in ABC trans-
porter expression (47, 58–60). If DOX impacts regulation of 
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BTN3A-dependent pAg sensing, then the use of such cytotoxic 
drugs in cancer treatment could impact immunotherapy strate-
gies based on γδ T cells (23) by selecting clones with increased 
expression of survival factors which promote tumor growth. In 
any event, expression of this subset of ABC transporters may 
act as a biomarker for enhanced Vγ9/Vδ2 T  cell activation by 
cytokine secretion, and it will be interesting to test this correla-
tion in other cells and with other markers of activation. Current 
experiments are underway to identify a more comprehensive 
catalog of differences between HeLa-L and HeLa-M cells.
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